HCV infection and the risk of head and neck cancer: A meta-analysis
RightsCopyright © 2020 Elsevier Ltd. All rights reserved.
MetadataShow full item record
Recent evidence has consistently suggested a role for HCV in the etiology of head and neck squamous cell carcinoma (HNSCC), but the conclusions of these studies have often been limited by small sample size. Therefore, a meta-analysis was performed to summarize present evidence on the association between HCV infection and HNSCC. After screening citations from literature search, eight observational studies investigating the association between HCV and cancer(s) of either oral cavity, oropharynx, hypopharynx or larynx were included. For each cancer site, risk ratios from individual studies were displayed in forest plots; pooled risk ratios (RR) and corresponding confidence intervals (CI) were calculated. A significant association was found between HCV infection and cancers of the oral cavity (RR = 2.13; 95%: 1.61-2.83), oropharynx (RR = 1.81; 95% CI: 1.21-2.72), and larynx (RR = 2.57; 95% CI: 1.11-5.94). A similar picture emerged for hypopharyngeal cancer, though this result did not fully reach statistical significance because of the small number of available studies (RR = 2.15; 95% CI: 0.73-6.31). These findings remained similar after exclusion of patients with HIV co-infection. Our results highlighted the importance of surveillance of the upper aerodigestive tract in patients with known chronic HCV infections in order to enable HNSCC early diagnosis. In addition, they could be a reminder of the possibility of undiagnosed HCV infection to the clinicians treating HNSCC.
CitationBorsetto D et al. HCV infection and the risk of head and neck cancer: A meta-analysis. Oral Oncol. 2020 Jun 26;109:104869. doi: 10.1016/j.oraloncology.2020.104869. Epub ahead of print.
Showing items related by title, author, creator and subject.
Did the 'Be Clear on Bowel Cancer' public awareness campaign pilot result in a higher rate of cancer detection? Bethune, Rob; Marshall, Morwena J.; Mitchell, S J; Oppong, C; Cartmel, M T; Arumugam, P J; Gee, A S; Daniels, Ian R. (BMJ, 2013-07)To assess the impact of a 7-week public bowel cancer awareness campaign pilot by reviewing the number of 2-week referrals from general practitioners (GPs) to hospital, endoscopic procedures and new cancers diagnosed ...
Clinical evidence of field cancerization in patients with oral cavity cancer in a betel quid chewing area. Liao, C-T; Wallace, Christopher G; Lee, L-Y; Hsueh, C; Lin, C-Y; Fan, K-H; Wang, H-M; Ng, S-H; Lin, C-H; Tsao, C-K; Chen, I-H; Huang, S-F; Kang, C-J; Yen, T-C (Elsevier, 2014-08)We sought to investigate whether there is evidence of field cancerization in patients with oral cavity squamous cell carcinoma (OSCC) enrolled in a betel quid chewing area. We also assessed whether betel quid chewing is ...
Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum Glynne-Jones, R.; Hava, N.; Goh, V.; Bosompem, S.; Bridgewater, J.; Chau, I.; Gaya, A.; Wasan, H.; Moran, B.; Melcher, L.; MacDonald, A.; Osborne, Melanie; Beare, S.; Jitlal, M.; Lopes, A.; Hall, M.; West, N.; Quirke, P.; Wong, W. L.; Harrison, M.; Bacchus, investigators (BioMed Central, 2015-10-23)BACKGROUND: In locally advanced rectal cancer (LARC) preoperative chemoradiation (CRT) is the standard of care, but the risk of local recurrence is low with good quality total mesorectal excision (TME), although many still ...